目的 探討胃康靈膠囊聯(lián)合雷貝拉唑鈉腸溶片治療胃潰瘍的臨床療效。方法 選取2018年1月—2020年12月在濮陽(yáng)市中醫(yī)醫(yī)院進(jìn)行治療的82例胃潰瘍患者為研究對(duì)象，根據(jù)用藥不同將所有患者分為對(duì)照組和治療組，每組各41例。對(duì)照組口服雷貝拉唑鈉腸溶片，20 mg/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服胃康靈膠囊，1.6 g/次，3次/d。兩組均連續(xù)治療6周比較效果。觀察兩組臨床療效，比較兩組臨床癥狀改善時(shí)間、胃腸激素水平和血清學(xué)指標(biāo)。結(jié)果 經(jīng)治療，治療組總有效率是97.56%，顯著高于對(duì)照組的80.49%（P＜0.05）。經(jīng)治療，治療組胃脘痛、納差、反酸、胃寒喜溫等中醫(yī)證候改善時(shí)間均顯著短于對(duì)照組（P＜0.05）。經(jīng)治療，兩組血清白細(xì)胞介素-6（IL-6）、白細(xì)胞介素-17（IL-17）、基質(zhì)金屬蛋白酶-9（MMP-9）、降鈣素原（PCT）水平均較治療前顯著降低，但表皮生長(zhǎng)因子（EGF）均顯著升高（P＜0.05）；且治療后，治療組血清炎癥因子水平改善優(yōu)于對(duì)照組（P＜0.05）。經(jīng)治療，兩組血清胃動(dòng)素（MTL）均較治療前顯著升高，但血清胃泌素（GAS）降低（P＜0.05）；治療后，治療組胃腸激素水平改善優(yōu)于對(duì)照組（P＜0.05）。結(jié)論 胃康靈膠囊聯(lián)合雷貝拉唑治療胃潰瘍具有較好的臨床療效，不僅可降低機(jī)體促炎因子水平，還可改善機(jī)體胃腸激素水平和臨床癥狀，有著良好臨床應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Weikangling Capsules combined with rabeprazole in treatment of gastric ulcer.Methods A total of 82 patients with gastric ulcer treated in Puyang Hospital of Traditional Chinese Medicine from January 2018 to December 2020 were selected as the research subjects. According to different medication, all patients were divided into control group and treatment group, with 41 cases in each group. Patients in the control group were po administered with Rabeprazole Sodium Enteric-coated Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Weikangling Capsules on the basis of the control group, 1.6 g/time, three times daily. The two groups were treated for 6 weeks to compare the effect. The clinical efficacy of the two groups was observed, and the improvement time of clinical symptoms, gastrointestinal hormone levels and serological indicators were compared between the two groups.Results After treatment, the total effective rate of the treatment group was 97.56%, significantly higher than that of the control group 80.49% (P < 0.05). After treatment, the improvement time of epigastric pain, poor appetite, acid reflux, cold and warm stomach syndrome in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, serum levels of interleukin-6 (IL-6), interleukin-17 (IL-17), matrix metalloproteinase-9 (MMP-9) and procalcitonin (PCT) in two groups were significantly decreased compared with before treatment, but epidermal growth factor (EGF) was significantly increased (P < 0.05). After treatment, the level of serum inflammatory factors in the treatment group was better than that in the control group (P < 0.05). After treatment, serum motilin (MTL) in both groups was significantly increased compared with before treatment, but serum gastrin (GAS) was decreased (P < 0.05). After treatment, the level of gastrointestinal hormone in the treatment group was better than that in the control group (P < 0.05).Conclusion Weikangling Capsules combined with rabeprazole has good clinical effect in treatment of gastric ulcer, and can not only reduce the level of proinflammatory factors, but also improve the level of gastrointestinal hormones and clinical symptoms, which has good clinical application value.

R975

河南省中醫(yī)藥科學(xué)研究專項(xiàng)課題（20-21ZY2192）